梗阻性肥厚型心肌病治疗新进展

New advances in the treatment of hypertrophic obstructive cardiomyopathy

在梗阻性肥厚型心肌病(HOCM)的治疗中,传统药物治疗虽能改善患者症状,但未能针对其发病机制延缓自然病程,存在局限性。外科室间隔心肌切除术疗效确切,却因创伤大、风险高而限制了其在临床上的广泛应用。同样,酒精室间隔消融术作为一种微创治疗手段,术后导致的房室传导阻滞等并发症也不容忽视。随着医学技术的不断进步,HOCM的治疗策略也在不断发展。本文旨在概述HOCM治疗领域的新进展。

In the treatment of hypertrophic obstructive cardiomyopathy(HOCM),traditional pharmacotherapy,while palliative for symptoms,fails to target the pathogenic mechanisms to retard the natural progression of the disease,thus exhibiting limitations in management.Although surgical septal myectomy offers definitive therapeutic outcomes,its widespread clinical application is constrained due to the significant invasiveness and elevated risk associated with the procedure.Similarly,the minimally invasive approach of alcohol septal ablation,while a less aggressive treatment option,cannot overlook the potential post-procedural complications such as atrioventricular block.With the continuous advancement of medical technology,treatment strategies for HOCM are evolving.This article aims to provide an overview of the recent advancements in the management of HOCM.